Both drugs prevented foot process effacement and attenuated urinary albumin excretion, thereby contributing to a deeper understanding of the renal protective mechanisms associated with sodium glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP4) inhibitors in diabetes [174]. Here, SLC5A2 is linked to diabetes mellitus.